EGFR and non-small cell lung carcinoma: EGFR‐TKI such as erlotinib (Rosell et al, 2012), gefitinib (Mok et al, 2009), and afatinib (Sequist et al, 2013) have shown clinical activity toward NSCLC, leading to their approval for the treatment of metastatic disease.